LP
KRYS icon

LMR Partners’s Krystal Biotech KRYS Stock Holding History

LMR Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-232
Closed -$41.2K – 1422
2024
Q3 		$42.2K Buy
+232
New +$44.7K ﹤0.01% 1084
2022
Q1 		– Sell
-4,884
Closed -$342K – 1288
2021
Q4 		$342K Buy
+4,884
New +$284K ﹤0.01% 997

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

LMR Partners's KRYS Position: Q4 2024 in Review

LMR Partners sold out of Krystal Biotech (KRYS) in Q4 2024, closing a stake of 232 shares — an estimated $41.2K sold.

LMR Partners first reported a position in KRYS in Q4 2021 and held it in 2 quarters. The position peaked at $342K in Q4 2021. 264 funds tracked by Wall St. Rank hold KRYS as of Q4 2024.

  • LMR Partners reported no remaining Krystal Biotech position as of Q4 2024 after selling out during the quarter.
  • LMR Partners sold 232 Krystal Biotech shares in Q4 2024, an estimated $41.2K.
  • LMR Partners first reported a position in Krystal Biotech in Q4 2021 and held it in 2 quarters.
  • LMR Partners's Krystal Biotech position peaked at $342K in Q4 2021.
  • 264 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2024.

Based on LMR Partners's 13F filing for Q4 2024, filed 14 Feb 2025.